CureVac N.V.
CVAC · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.33 | -0.05 | 0.05 | -0.00 |
| FCF Yield | -4.20% | -7.27% | -9.36% | 59.24% |
| EV / EBITDA | -12.38 | -3.75 | -8.48 | 0.22 |
| Quality | ||||
| ROIC | -9.80% | -8.04% | -5.05% | 43.92% |
| Gross Margin | -77.75% | 2.02% | 89.73% | 95.56% |
| Cash Conversion Ratio | 0.70 | 0.80 | 1.73 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 128.34% | 138.55% | 118.54% | 99.48% |
| Free Cash Flow Growth | -4.14% | 39.41% | -119.71% | 464.44% |
| Safety | ||||
| Net Debt / EBITDA | 6.49 | 8.58 | 12.69 | -1.36 |
| Interest Coverage | -109.28 | -164.35 | 68.80 | 2,612.62 |
| Efficiency | ||||
| Inventory Turnover | 4.09 | 1.62 | 2.75 | 46.66 |
| Cash Conversion Cycle | 270.46 | 170.75 | -808.66 | -49.34 |